Pharmosa Biopharm
國邑藥品科技股份有限公司
Pharmosa Biopharm is a Taiwan TPEx-listed biotechnology company; its most advanced asset is L606 (Phase 3; recruiting, Pulmonary Hypertension Due to Lung Disease (Disorder)), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| L606 | Liposomal treprostinil | Phase 3; recruiting | Pulmonary Hypertension Due to Lung Disease (Disorder) | Australia, Austria, Belgium, Canada, France, Germany, Italy, Latvia, Portugal, Spain, United Kingdom, United States | 2026-10-14 | Trial registry |
| L608 | Liposomal iloprost | Phase 2 trial authorized | Systemic sclerosis-associated digital ulcers | United States | 2026-09-18 | Company disclosure |
Key events
- L606 Phase 3 Re-Spire enrollment and partner patent-litigation update (company disclosure)
- L608 Phase 2 trial authorization announced (company disclosure)